Chapter 6

DIFFERENTIATION OF SEROUS OVARIAN TUMORS

Özgür İLHAN ÇELİK¹

Introduction

Surface epithelial tumors are the most common tumors of the ovaries. They compose 90% of all ovarian cancers. The origin of these tumors are the modified mesothelium of the ovarian surface and the underlying ovarian stroma (Prat, 2004). Epithelial tumors of the ovary are classified according to their epithelial component by World Health Organization (WHO). Among the surface epithelial tumors, serous tumors are the most frequent group (Testa & et al., 2018). The subtypes of serous tumors are benign, borderline and malignant as presented in the Table (Kurman & et al, 2014).

Table: Classification of Serous Ovarian Tumors (WHO-2014)

Serous Tumors	Benign	Serous Cystadenoma
		Serous Adenofibroma
		Serous Surface Papilloma
	Borderline	Serous Borderline Tumor/ Atypical Proliferative Serous Tumor
		Serous Borderline Tumor-Micropapillary variant/ Non-invasive Low-grade Serous Carcinoma
	Malignant	Low-grade Serous Carcinoma
		High-grade Serous Carcinoma

Serous Tumors

Serous Tumors account for 30-40% of all ovarian tumors. 70% of them are benign, 5-10% are borderline and 20-25% are malignant.

Serous Benign Tumors

This group of tumors are mostly seen in women with an age range of 40 to 60. They are generally asymptomatic and found out incidentally during the ultrasound examination of the pelvic region for other disorders.

¹Assist. Prof. Dr, Muğla Sıtkı Koçman University, Faculty of Medicine, Department of Pathology, oilhancelik@gmail.com

Health Sciences Surgical Sciences

References

Bell, D.A., Weinstock M.A. & Scully, R.E. (1988). Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. *Cancer 62*, 2212-2222.

Bell, K.A., Smith Sehdev, A.E. & Kurman, R.J. (2001). Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. *American Journal of Surgical Pathology, 25,* 419-32.

Bookman, M.A. (2012). First-line chemotherapy in epithelial ovarian cancer. *Clinical Obstetrics and Gynecology* 55, 96-113.

Diebold J. (2014). Serous ovarian tumors. Pathologe.35 (4), 314-321.

Gershenson, D.M., Sun, C.C., Bodurka, D., Coleman, R.L., Lu, K.H., Sood, A.K., Daevers, M., Malpica, A.L. & Kavanagh, J.J. (2009). Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. *Gynecological Oncology*, 114, 48-52.

Kurman, R.J., Carcangiu, M.L., Herrington, C.S. & Young, R.H. (2014). WHO Classification of tumours of female reproductive organs. (4th edition). Lyon, France: IARC.

Malpica, A., Deavers, M.T., Tornos, C., Kurman, R.J., Soslow, R., Seidman; S.D., Munsel, M.F., Gaertner, E., Frishberg, D. & Silva, E.G. (2007). Interobserver and intraobserver varibility of a two-tier system forgrading ovarianserous carcinoma. *American Journal of Surgical Pathology*, *3*, 1168-1174.

McCaughey, W.T., Kirk., M.E., Lester, W. & Dardick, I. (1984). Peritoneal epithelial lesions associated with proliferative serous tumors of ovary. *Histopathology 8*, 195-208.

Mutter, G.L., Matias-Guiu, X. & Lax, S.F. (2009). Endometrial adenocarcinoma. Stanley Robboy (Ed). in Robboy's Pathology of the Female Reproductive Tract (393-426). China. Elsevier.

Prat J. (2004). Pathology of the ovary. Philadelphia: Saunders: 83-109.

Roma, A., Malpica A.A., Deavers, M.P. & Silva, E.G. (2008). Ovarian serous borderline tumors with a predominant micropapillary pattern are agressive neoplasms with an increased risk of low-grade serous carcinoma. *Modern Pathology 21*, 221A.

Seidman J.D., Kurman R.J. (2000). Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. *Human Pathology* 31(5): 539–557.

Seidman, S.D. & Kurman, R.J. (2000). Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. *Human Pathology*, *31*, 539-557.

Shvartsmann, H.S., Sun, CC., Bodurka, D.C., Mahajan, V., Crispens, M., Lu, K.H., Deavers, M.T., Malpica, A., Silva, E.G. & Gershenson, D.M. (2007). Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. *Gynecological Oncology*, 105, 625-629.

Sneige, N., Thomison, J.B., Malpica, A., Gong, Y., Ensor, J. & Silva, E.G. (2012). Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome. *Cancer Cytopathology*, 120(4), 10.1002/cncy.21219.

Testa, U., Petrucci, E., Pasquini, L., Castelli, G. & Pelosi, E. (2018). Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. *Medicines (Basel), 5(1):* 16. Published online 2018 Feb 1. doi: 10.3390/medicines5010016.

Vang, R., Hannibal, C.G., Junge, J., Frederiksen, K., Kjaer, S.K. & Kurman, RJ. (2017). Long-term Behavior of Serous Borderline Tumors Subdivided into Atypical Proliferative Tumors and Non-invasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. *American Journal of Surgical Pathology*, 41,6, 725–737.

Vang, R., Shih, I. & Kurman, R.J. (2009). Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features and diagnostic problems. *Advanced Anatomic Pahology* 16,267-282.

Wong K.K., Gershenson D. (2007). The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. *Disease Markers*, 23(5-6): 377-387.